First, TTC17 may function throughout the metastatic process of breast cancer (tumor cells break through the basement membrane into the lymphatic and blood circulation and finally attach to distant sites and form new lesions), and its expression changes to gradually decrease, so its expression is less reduced in the mPT. This evidence concerns the gene TTC17 and breast carcinoma.